Athena Heart [310] Instant

: Classified as Category X ; it may cause fetal harm and should not be used by pregnant women. Drug Interactions :

It is intended to reduce the risk of hospitalization for AF. 3. Safety and Contraindications

Based on the code , this guide provides a breakdown of the ATHENA clinical trial (A Trial with dronedarone to prevent Hospitalization or death in patients with Atrial fibrillation) and the associated use of dronedarone (brand name Multaq ) for cardiovascular health. 1. Overview of the ATHENA Trial ATHENA HEART [310]

: Dronedarone significantly reduced the primary composite endpoint of first cardiovascular hospitalization or death by 24% compared to a placebo.

: Contraindicated in patients with symptomatic heart failure or recent hospitalization for heart failure (NYHA Class IV or symptomatic Class II-III). : Classified as Category X ; it may

: Conduct regular ECGs to monitor for potential proarrhythmic effects or excessive QT prolongation.

Patients with paroxysmal or persistent AF or AFL who are in sinus rhythm or who will be cardioverted. Safety and Contraindications Based on the code ,

: The trial established dronedarone as a rhythm-control therapy specifically aimed at reducing clinical complications rather than just maintaining sinus rhythm. 2. Dronedarone (Multaq) Usage Guide